Literature DB >> 1909090

Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

M E Grace1, A Berg, G S He, L Goldberg, M Horowitz, G A Grabowski.   

Abstract

To investigate the molecular basis for the distinct neuronopathic phenotypes of Gaucher disease, acid beta-glucosidases expressed from mutant DNAs in Gaucher disease type 2 (acute) and type 3 (subacute) patients were characterized in fibroblasts and with the baculovirus expression system in insect cells. Expression of the mutant DNA encoding a proline-for-leucine substitution at amino acid 444 (L444P) resulted in a catalytically defective, unstable acid beta-glucosidase in either fibroblasts from L444P/L444P homozygotes or in insect cells. This mutation was found to be homoallelic in subacute neuronopathic (type 3) Gaucher disease. In comparison, expression of the mutant cDNA encoding an arginine-for-proline substitution at amino acid 415 (P415R) resulted in an inactive and unstable protein in insect cells. This allele was found only in a type 2 patient with the L444P/P415R genotype. The substantial variation in the type 3 phenotype (L444P homozygotes) suggests the complex nature of the molecular basis of phenotypic variation in Gaucher disease. Yet, the association of neuronopathic phenotypes with alleles producing severely compromised (L444P) or functionally null (P415R) enzymes indicates that the effective level of residual activity at the lysosome is likely to be a major determinant of the severity of Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909090      PMCID: PMC1683149     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  48 in total

1.  beta-Glucoside hydrolase activity of normal and glucosylceramidotic cultured human skin fibroblasts.

Authors:  O T Mueller; A Rosenberg
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

2.  Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations.

Authors:  E H Kolodny; N Firon; N Eyal; M Horowitz
Journal:  Am J Med Genet       Date:  1990-08

3.  The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA.

Authors:  J W Taylor; W Schmidt; R Cosstick; A Okruszek; F Eckstein
Journal:  Nucleic Acids Res       Date:  1985-12-20       Impact factor: 16.971

4.  Supercoil sequencing: a fast and simple method for sequencing plasmid DNA.

Authors:  E Y Chen; P H Seeburg
Journal:  DNA       Date:  1985-04

5.  A glucocerebrosidase fusion gene in Gaucher disease. Implications for the molecular anatomy, pathogenesis, and diagnosis of this disorder.

Authors:  A Zimran; J Sorge; E Gross; M Kubitz; C West; E Beutler
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

6.  Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations.

Authors:  M E Grace; P N Graves; F I Smith; G A Grabowski
Journal:  J Biol Chem       Date:  1990-04-25       Impact factor: 5.157

7.  Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene.

Authors:  N Firon; N Eyal; E H Kolodny; M Horowitz
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

8.  Gaucher disease associated with a unique KpnI restriction site: identification of the amino-acid substitution.

Authors:  E Beutler; T Gelbart
Journal:  Ann Hum Genet       Date:  1990-05       Impact factor: 1.670

9.  Sequence of two alleles responsible for Gaucher disease.

Authors:  C M Hong; T Ohashi; X J Yu; S Weiler; J A Barranger
Journal:  DNA Cell Biol       Date:  1990-05       Impact factor: 3.311

10.  Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene.

Authors:  N Dahl; M Lagerström; A Erikson; U Pettersson
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

View more
  10 in total

1.  Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Authors:  Benjamin Liou; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2009-02-13       Impact factor: 4.797

2.  Overexpression of human glucocerebrosidase containing different-sized leaders.

Authors:  M Pasmanik-Chor; O Elroy-Stein; H Aerts; V Agmon; S Gatt; M Horowitz
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

3.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 4.  The glucocerebrosidase locus in Gaucher's disease: molecular analysis of a lysosomal enzyme.

Authors:  P K Mistry; T M Cox
Journal:  J Med Genet       Date:  1993-11       Impact factor: 6.318

5.  Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients.

Authors:  M E Grace; R J Desnick; G M Pastores
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

6.  Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease.

Authors:  M E Grace; P Ashton-Prolla; G M Pastores; A Soni; R J Desnick
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 7.  The use of baculoviruses as expression vectors.

Authors:  I M Kidd; V C Emery
Journal:  Appl Biochem Biotechnol       Date:  1993 Aug-Sep       Impact factor: 2.926

8.  Gaucher disease: A G+1----A+1 IVS2 splice donor site mutation causing exon 2 skipping in the acid beta-glucosidase mRNA.

Authors:  G S He; G A Grabowski
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

9.  Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications.

Authors:  A Sibille; C M Eng; S J Kim; G Pastores; G A Grabowski
Journal:  Am J Hum Genet       Date:  1993-06       Impact factor: 11.025

10.  In Silico Analysis of Missense Mutations as a First Step in Functional Studies: Examples from Two Sphingolipidoses.

Authors:  Ana Joana Duarte; Diogo Ribeiro; Luciana Moreira; Olga Amaral
Journal:  Int J Mol Sci       Date:  2018-10-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.